BCRX · Insider trading · 13F holders · Congress trades
Biocryst Pharmaceuticals Inc (BCRX)
Who is buying and selling BCRX: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 21
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $0
- Congress trades, 12 months
- 2
BCRX at a glance
- No open-market insider purchases or sales of BCRX were filed in the last 90 days.
- 21 13F filers hold BCRX among their 50 largest positions, worth $774.7M combined, including James Flynn, Joseph Edelman and Peter Kolchinsky. The biggest bets by portfolio weight are Rosalind Advisors, Inc. (2.7%), TCG Crossover Management, LLC (2.6%) and Vestal Point Capital, LP (1.9%). In their latest 13Fs, 2 managers opened a new position and 2 added to one.
- Members of Congress have disclosed 5 BCRX trades since 2022, 2 purchases and 0 sales in the past year; the latest was Gilbert Ray Cisneros, Jr. (D-CA), buying $1K–15K on Jul 10, 2026.
- BCRX last closed at $8.43 on Oct 30, 2026.
BCRX insider trading
No open-market insider purchases or sales of BCRX were filed in the last 90 days.
Who owns BCRX? Hedge funds and superinvestors
21 13F filers hold BCRX among their 50 largest positions, worth $774.7M combined, including James Flynn, Joseph Edelman and Peter Kolchinsky. The biggest bets by portfolio weight are Rosalind Advisors, Inc. (2.7%), TCG Crossover Management, LLC (2.6%) and Vestal Point Capital, LP (1.9%). In their latest 13Fs, 2 managers opened a new position and 2 added to one.
Superinvestors holding BCRX: James Flynn 1.9% · Joseph Edelman 1.6% · Peter Kolchinsky 1.4%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Peter KolchinskyHedge fund | 1.4% | $158.3M | 15,827,186 | +0.0% shares | Q2 2026 |
| James FlynnHedge fund | 1.9% | $151.0M | 15,096,403 | +0.4% shares | Q2 2026 |
| TCG Crossover Management, LLCHedge fund | 2.6% | $110.2M | 11,020,968 | +0.0% shares | Q2 2026 |
| Joseph EdelmanHedge fund | 1.6% | $103.1M | 10,308,888 | +38.7% shares | Q2 2026 |
| Vestal Point Capital, LPHedge fund | 1.9% | $83.0M | 8,300,000 | +18.1% shares | Q2 2026 |
| Frazier Life Sciences Management, L.P.Hedge fund | 0.9% | $40.1M | 4,009,240 | +0.0% shares | Q2 2026 |
| Kynam Capital Management, LPHedge fund | 1.4% | $25.2M | 2,522,660 | -55.6% shares | Q2 2026 |
| Rice Hall James & Associates, LLCAsset manager | 1.1% | $23.3M | 2,332,043 | +4.6% shares | Q2 2026 |
| Nantahala Capital Management, LLCHedge fund | 1.2% | $19.0M | 1,901,160 | -4.3% shares | Q2 2026 |
| Eversept Partners, LPHedge fund | 1.0% | $18.7M | 1,865,653 | -38.6% shares | Q2 2026 |
| Parkman Healthcare Partners LLCHedge fund | 1.7% | $16.2M | 1,624,279 | -4.9% shares | Q2 2026 |
| Rosalind Advisors, Inc.Investment manager | 2.7% | $7.2M | 721,504 | -21.8% shares | Q2 2026 |
| Elmind Capital, LPHedge fund | 1.3% | $5.2M | 520,000 | -48.0% shares | Q2 2026 |
| Nan Fung Trinity (HK) LtdInvestment manager | 0.4% | $4.5M | 450,000 | — | Q2 2026 |
| DAFNA Capital Management LLCHedge fund | 0.8% | $4.0M | 400,248 | -7.0% shares | Q2 2026 |
| Doliver Advisors, LPInvestment manager | 0.6% | $2.5M | 304,328 | -18.7% shares | Q3 2026 |
| QTR Family Wealth, LLCWealth manager | 0.6% | $1.6M | 161,082 | +2.6% shares | Q2 2026 |
| Marble Bar Asset Management LLPHedge fund | 0.4% | $623K | 62,339 | -34.0% shares | Q2 2026 |
| Cannon Global Investment Management, LLCHedge fund | 1.8% | $597K | 59,700 | — | Q2 2026 |
| Bender Robert & AssociatesInvestment manager | 0.0% | $198K | 23,710 | New | Q3 2026 |
| Parametrica Management LtdInvestment manager | 0.1% | $128K | 15,401 | New | Q3 2026 |
Each manager counts with its latest 13F (Q3 2026: 3, Q2 2026: 18). Screen BCRX in the grand portfolio →
BCRX stock trades by members of Congress
Members of Congress have disclosed 5 BCRX trades since 2022, 2 purchases and 0 sales in the past year; the latest was Gilbert Ray Cisneros, Jr. (D-CA), buying $1K–15K on Jul 10, 2026.
| Filed | Member | Trade | Amount | Traded | Since |
|---|---|---|---|---|---|
| Sep 4, 2026 | Gilbert Ray Cisneros, Jr.D-CA · House | Buy | $1K–15K | Jul 10, 2026 | -19.3% |
| Dec 15, 2025 | Gilbert Ray Cisneros, Jr.D-CA · House | Buy | $1K–15K | Nov 13, 2025 | +22.2% |
| Nov 11, 2023 | Josh GottheimerD-NJ · House | Buy | $1K–15K | Oct 16, 2023 | +41.9% |
| Oct 15, 2023 | Josh GottheimerD-NJ · House | Sale | $1K–15K | Sep 15, 2023 | +23.1% |
| Sep 16, 2022 | Josh GottheimerD-NJ · House | Buy | $1K–15K | Aug 11, 2022 | -41.3% |
2 members have traded BCRX: Gilbert Ray Cisneros, Jr., Josh Gottheimer.
BCRX questions and answers
Are insiders buying BCRX stock?
No open-market insider purchases or sales of BCRX were filed in the last 90 days.
Which hedge funds own BCRX?
21 13F filers hold BCRX among their 50 largest positions, worth $774.7M combined, including James Flynn, Joseph Edelman and Peter Kolchinsky. The biggest bets by portfolio weight are Rosalind Advisors, Inc. (2.7%), TCG Crossover Management, LLC (2.6%) and Vestal Point Capital, LP (1.9%). In their latest 13Fs, 2 managers opened a new position and 2 added to one.
Has Congress traded BCRX?
Members of Congress have disclosed 5 BCRX trades since 2022, 2 purchases and 0 sales in the past year; the latest was Gilbert Ray Cisneros, Jr. (D-CA), buying $1K–15K on Jul 10, 2026.
Who is the largest holder of BCRX?
Among 13F filers, Peter Kolchinsky reports the largest BCRX position, $158.3M (15,827,186 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Rosalind Advisors, Inc.'s: 2.7% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.